Title: Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Journal: The New England journal of medicine 20170601
Title: Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects.
Journal: Antimicrobial agents and chemotherapy 20170501
Title: Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
Journal: Antimicrobial agents and chemotherapy 20160901
Title: A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
Journal: Journal of viral hepatitis 20151201
Title: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.
Journal: Canadian journal of gastroenterology & hepatology 20150101
Title: Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.
Journal: Scientific reports 20140101
Title: Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
Journal: Journal of virology 20110701
Title: Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5368-78.
Title: Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
